This study investigates pancreatic cancer. The purpose of this study is to evaluate a new approach using radiation therapy combined with systemic therapy for patients with this condition.

The study focuses on evaluating the safety and effectiveness of the PULSAR strategy combined with proton beam therapy. This approach investigates improving local control of the disease while reducing side effects from radiation.

• Who can participate: Adults aged 19 years and older with pancreatic ductal adenocarcinoma can participate if they have completed 2-4 cycles of first-line systemic therapy and have measurable disease suitable for radiotherapy.
• Study details: Participants will receive PULSAR-based adaptive proton radiotherapy after systemic therapy. A placebo is not used in this study.